Publications by Aurélien Lathuilière

Plasma biomarkers for Alzheimer's disease: a field-test in a memory clinic

Background The key Alzheimer's disease (AD) biomarkers are traditionally measured with techniques/exams that are either expensive (amyloid-positron emission tomography (PET) and tau-PET), invasive (cerebrospinal fluid A beta 42 and p-tau 181), or poorly sp ...

BMJ PUBLISHING GROUP2023

Encapsulation device

Nicolas Bouche, Bernard Schneider, Aurélien Lathuilière

2018

A subcutaneous cellular implant for passive immunization against amyloid-beta reduces brain amyloid and tau pathologies

Patrick Aebischer, Bernard Schneider, Vanessa Laversenne, Aurélien Lathuilière, Marco Stampanoni

Passive immunization against toxic misfolded proteins could offer protection against neurodegenerative disease. LathuiliSre et al. report the development of a retrievable device to encapsulate cells secreting recombinant anti-amyloid-beta antibodies. When ...

Oxford Univ Press2016

Encapsulation device

Nicolas Bouche, Bernard Schneider, Aurélien Lathuilière

Provided herein is a cell encapsulation device comprising an internal chamber suitable for holding biological agents, wherein the internal chamber is disposed between a first semipermeable layer and a second semi-permeable layer, and the first and second s ...

2016

Encapsulated Cellular Implants for Recombinant Protein Delivery and Therapeutic Modulation of the Immune System

Bernard Schneider, Aurélien Lathuilière

Ex vivo gene therapy using retrievable encapsulated cellular implants is an effective strategy for the local and/or chronic delivery of therapeutic proteins. In particular, it is considered an innovative approach to modulate the activity of the immune syst ...

MDPI2015

Genetic engineering of cell lines using lentiviral vectors to achieve antibody secretion following encapsulated implantation

Patrick Aebischer, Bernard Schneider, Marc Moniatte, Aurélien Lathuilière

The controlled delivery of antibodies by immunoisolated bioimplants containing genetically engineered cells is an attractive and safe approach for chronic treatments. To reach therapeutic antibody levels there is a need to generate renewable cell lines, wh ...

Elsevier2014

A high-capacity cell macroencapsulation system supporting the long-term survival of genetically engineered allogeneic cells

Patrick Aebischer, Matthias Lütolf, Bernard Schneider, Steffen Cosson, Aurélien Lathuilière

The rapid increase in the number of approved therapeutic proteins, including recombinant antibodies, for diseases necessitating chronic treatments raises the question of the overall costs imposed on healthcare systems. It is therefore important to investig ...

Elsevier2014

A novel encapsulation device for peripheral implantation of antibody-secreting cells : passive immunization against amyloid β

Aurélien Lathuilière

Alzheimer’s disease (AD) is the most prevalent form of dementia in the elderly. As populations are aging in most parts of the world, the number of people with Alzheimer’s disease is expected to dramatically increase. This devastating neurodegenerative diso ...

EPFL2013